Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Sangamo Biosciences, retaining the price target of $10.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick Trucchio has given his Buy rating due to a combination of factors that suggest Sangamo Biosciences is poised for significant value creation in the near future. The company’s Phase 1/2 STAAR trial for Fabry disease has shown promising results across various health metrics, reducing the risk associated with the program and setting the stage for a potential first-in-class approval and commercial launch in the second half of 2026. This is further supported by the planned submission of a biologics license application in the first quarter of 2026 under the FDA’s Accelerated Approval pathway.
Moreover, Sangamo has initiated a neurology clinical trial for ST-503 in idiopathic small fiber neuropathy, with proof-of-efficacy data expected by the fourth quarter of 2026. The company’s proprietary STAC-BBB capsid technology, which has attracted significant pharmaceutical partnerships, and the next-generation modular integrase platform, which offers potential for further collaborations, also contribute to the positive outlook. With multiple upcoming data readouts, regulatory filings, and business development milestones, Trucchio sees a compelling opportunity for value inflection, particularly with the promising data from the STAAR trial supporting the anticipated BLA submission.